https://scholars.lib.ntu.edu.tw/handle/123456789/582180
標題: | Two Decades of Universal Hepatitis B Vaccination in Taiwan: Impact and Implication for Future Strategies | 作者: | YEN-HSUAN NI LI-MIN HUANG MEI-HWEI CHANG CHUNG-JEN YEN CHUN-YI LU You S. JIA-HORNG KAO Lin Y. HUEY-LING CHEN HONG-YUAN HSU DING-SHINN CHEN |
公開日期: | 2007 | 出版社: | W.B. Saunders | 卷: | 132 | 期: | 4 | 起(迄)頁: | 1287-1293 | 來源出版物: | Gastroenterology | 摘要: | Background & Aims: Following the world's first successful implementation of a universal hepatitis B virus (HBV) vaccination program for infants in Taiwan 20 years ago, we performed this study to evaluate the long-term protection afforded by HBV vaccination and to rationalize further prevention strategies. Methods: HBV seromarkers, including hepatitis B surface antigen (HBsAg) and antibodies to HBsAg (anti-HBs) and core antigen (anti-HBc), were studied in 18,779 subjects from neonates to adults below 30 years of age in 2004. The birth cohort effect was evaluated by comparing the results of the same birth cohorts at different ages among this survey and the previous 1984, 1989, 1994, and 1999 surveys. Results: The seropositive rates for HBsAg, anti-HBs, and anti-HBc were 1.2%, 50.5%, and 3.7%, respectively, in those born after the vaccination program (<20 years of age) in 2004. A positive maternal HBsAg status was found in 89% of the HBsAg seropositive subjects born after the vaccination program. The absence of an increase in HBsAg seropositive subjects at different ages in the same birth cohorts born after the vaccination program implied no increased risk of persistent HBV infection with aging. Conclusions: Universal HBV vaccination provides long-term protection up to 20 years, and a universal booster is not indicated for the primary HBV vaccinees before adulthood. Maternal transmission is the primary reason for vaccine failure and is the challenge that needs to be addressed in future vaccination programs. This may include an appropriate hepatitis B immunoglobulin administration strategy for high-risk infants and involve efforts to minimize noncompliance. ? 2007 AGA Institute. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-34247209063&doi=10.1053%2fj.gastro.2007.02.055&partnerID=40&md5=c5d957f34e732b67239c1f9818ee2426 https://scholars.lib.ntu.edu.tw/handle/123456789/582180 |
ISSN: | 0016-5085 | DOI: | 10.1053/j.gastro.2007.02.055 | SDG/關鍵字: | hepatitis B antibody; hepatitis B core antigen; hepatitis B surface antibody; hepatitis B surface antigen; hepatitis B vaccine; recombinant hepatitis B vaccine; aging; article; cohort analysis; controlled study; drug treatment failure; hepatitis B; high risk population; human; infection prevention; infection risk; major clinical study; priority journal; seroepidemiology; Taiwan; vaccination; vertical transmission; virus transmission |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。